Evaluation of response criteria in rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs.
Biologic disease-modifying anti-rheumatic drugs (bDMARDs) used for rheumatoid arthritis (RA) have several mechanisms of action. Interleukin-6 inhibitors (IL-6i) block the production of acute-phase reactants (APRs), which are some of the composite measures of disease activity. In this study, we examined agreement between the European League Against Rheumatism (EULAR) response based on ESR or CRP, the Simplified Disease Activity Index 50% (SDAI50), and the Clinical Disease Activity Index 50% (CDAI50) response measures in patients treated with IL-6i and other bDMARDs. We enrolled 306 RA patients who started or switched bDMARDs. Treatment response at 6 months was analyzed. Kappa statistics were used to evaluate the agreement between different response measures. The contribution of APRs to improvement in disease activity scores was examined. Change of Health Assessment Questionnaire (HAQ) score was analyzed in IL-6i-treated patients. Good agreement was achieved between response measures, with a κ >0.6 in patients treated with tumor necrosis factor inhibitors or cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin fusion protein. In IL-6i-treated patients, the agreement was low between the EULAR response (ESR) and the SDAI50 or the CDAI50 (κ, 0.43 and 0.37, respectively). Under IL-6i treatment, APR improvement accounted for 56.0% of total improvement of the DAS28-ESR. When discordance was found between the CDAI50 and EULAR response in IL-6i-treated patients, all patients were classified as EULAR-only responders; there was no HAQ improvement in EULAR-only responders. EULAR response criteria overestimate the response under IL-6i treatment because the APR improvement largely contributes to the DAS28 improvement. This article is protected by copyright. All rights reserved.